| Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic Purpura (iTTP) (NCT05263193) | Sanofi | 2022-06-08 |
| First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic Participants (NCT05366764) | Sanofi | 2022-06-08 |
| Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (NCT05245071) | Sanofi | 2022-06-01 |
| Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD (NCT05326412) | Sanofi | 2022-05-19 |
| A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease (NCT05280548) | Sanofi | 2022-05-03 |
| A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy Participants (NCT05796479) | Sanofi | 2022-04-28 |
| Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (NCT05222906) | Sanofi | 2022-04-18 |
| Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) (NCT05237284) | Sanofi | 2022-04-13 |
| Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function (NCT05283915) | Sanofi | 2022-03-18 |
| A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease (NCT05206773) | Sanofi | 2022-03-11 |
| Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants. (NCT05282030) | Sanofi | 2022-03-10 |
| A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B) (NCT05797753) | Sanofi | 2022-02-18 |
| Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity (NCT05128773) | Sanofi | 2022-02-17 |
| A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359) (NCT05235724) | Sanofi | 2022-02-17 |
| Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) (NCT05263206) | Sanofi | 2022-02-15 |
| Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus (NCT05114590) | Sanofi | 2022-01-27 |
| A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries (NCT05214326) | Sanofi | 2022-01-18 |
| Comparative Efficacy of Cemiplimab to Historical Standard of Care in France (NCT05302297) | Sanofi | 2022-01-17 |
| Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma (NCT05097287) | Sanofi | 2021-12-16 |
| Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma (NCT05104892) | Sanofi | 2021-12-12 |
| First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (NCT05086315) | Sanofi | 2021-12-08 |
| Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA) (NCT05002777) | Sanofi | 2021-12-07 |
| A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] (NCT05179603) | Sanofi | 2021-12-07 |
| Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis (NCT05132569) | Sanofi | 2021-12-03 |
| Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine (NCT05107115) | Sanofi | 2021-11-24 |
| Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector (NCT05129241) | Sanofi | 2021-11-18 |
| A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in France (NCT06949358) | Sanofi | 2021-11-18 |
| Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer (NCT05071053) | Sanofi | 2021-11-16 |
| Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic Function (NCT05126329) | Sanofi | 2021-11-15 |
| Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan (NCT05132127) | Sanofi | 2021-11-11 |
| Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus (NCT05039840) | Sanofi | 2021-11-10 |
| A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®) (NCT05070663) | Sanofi | 2021-11-04 |
| Efficacy and Safety of FIRTECH in Patients With Mild to Moderate Acute Low Back Pain (NCT05137041) | Sanofi | 2021-11-04 |
| Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients (NCT05087212) | Sanofi | 2021-10-22 |
| Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52) (NCT05049122) | Sanofi | 2021-10-22 |
| Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single and Repeated Doses of SAR444336 in Healthy Adult Participants (NCT05876767) | Sanofi | 2021-10-15 |
| A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care Setting (NCT05073783) | Sanofi | 2021-10-14 |
| A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults (NCT06326814) | Sanofi | 2021-10-11 |
| A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204) (NCT05061420) | Sanofi | 2021-10-08 |
| EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients (NCT04998604) | Sanofi | 2021-09-27 |
| Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial Fibrillation (NCT05279833) | Sanofi | 2021-09-24 |
| A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) (NCT04914897) | Sanofi | 2021-09-23 |
| Pharmacokinetic Study to Compare Itepekimab Exposure When Administered With an Autoinjector Versus Prefilled Syringe (NCT06114238) | Sanofi | 2021-09-16 |
| Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA) (NCT04661033) | Sanofi | 2021-09-09 |
| Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis (NCT05018806) | Sanofi | 2021-09-09 |
| Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa (NCT04910776) | Sanofi | 2021-09-01 |
| Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A (NCT05042440) | Sanofi | 2021-08-11 |
| Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants (NCT04982991) | Sanofi | 2021-08-05 |
| A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2) (NCT05797701) | Sanofi | 2021-07-28 |
| A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201) (NCT04913220) | Sanofi | 2021-07-15 |
| A Non-Interventional National Study in Pediatric Patients With Unexplained Enlarged Spleen (NCT04845958) | Sanofi | 2021-06-30 |
| Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women (NCT04940026) | Sanofi | 2021-06-15 |
| Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults (NCT05976386) | Sanofi | 2021-06-08 |
| Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs (NCT04980027) | Sanofi | 2021-06-07 |
| Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis (NCT04879628) | Sanofi | 2021-06-07 |
| A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period (NCT05002933) | Sanofi | 2021-05-20 |
| Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis (NCT04823130) | Sanofi | 2021-04-22 |
| Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors (NCT04717375) | Sanofi | 2021-04-11 |
| Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus (NCT04781816) | Sanofi | 2021-04-01 |
| Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors (NCT04659603) | Sanofi | 2021-03-29 |
| Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ (NCT04656600) | Sanofi | 2021-03-02 |
| Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis (NCT04718870) | Sanofi | 2021-02-19 |
| Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (NCT04751487) | Sanofi | 2021-02-12 |
| Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat (NCT04705051) | Sanofi | 2021-02-09 |
| Dupilumab in Japanese Patients With Atopic Dermatitis (NCT04678882) | Sanofi | 2021-01-15 |
| Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (NCT04701983) | Sanofi | 2020-12-16 |
| Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS) (NCT04681729) | Sanofi | 2020-12-10 |
| A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy (NCT04669041) | Sanofi | 2020-12-08 |
| Dupilumab in CRSsNP (NCT04678856) | Sanofi | 2020-12-02 |
| Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI) (NCT04684524) | Sanofi | 2020-12-01 |
| Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants (NCT05795907) | Sanofi | 2020-11-30 |
| Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS) (NCT04572841) | Sanofi | 2020-11-12 |
| Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT) (NCT04550962) | Sanofi | 2020-11-02 |
| Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (NCT04478266) | Sanofi | 2020-10-14 |
| Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES) (NCT04411641) | Sanofi | 2020-09-24 |
| To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease (NCT04143958) | Sanofi | 2020-09-01 |
| Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) (NCT04394624) | Sanofi | 2020-08-31 |
| A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (NCT04458831) | Sanofi | 2020-08-13 |
| A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma (NCT04502862) | Sanofi | 2020-08-10 |
| Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants (NCT06106074) | Sanofi | 2020-08-10 |
| First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL (NCT04401020) | Sanofi | 2020-07-24 |
| A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19 (NCT04469621) | Sanofi | 2020-07-17 |
| Dupilumab Skin Barrier Function Study in Atopic Dermatitis (NCT04447417) | Sanofi | 2020-07-16 |
| Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation (NCT04456673) | Sanofi | 2020-07-06 |
| A Study of the Safety, Tolerability, and Bioequivalence of Orally Administered Venglustat in Healthy Adult Participants (NCT06418607) | Sanofi | 2020-06-23 |
| The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma (NCT04400318) | Sanofi | 2020-06-20 |
| A Study of the Safety, Tolerability, and Bioavailability of Orally Administered Venglustat in Healthy Adult Participants (NCT06418620) | Sanofi | 2020-06-18 |
| Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation (NCT04294459) | Sanofi | 2020-06-18 |
| Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma (NCT04270409) | Sanofi | 2020-06-16 |
| Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) (NCT04410991) | Sanofi | 2020-06-11 |
| Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies (NCT04418661) | Sanofi | 2020-06-09 |
| Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age (NCT04368429) | Sanofi | 2020-05-22 |
| Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks (NCT04410965) | Sanofi | 2020-05-20 |
| Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects (NCT06064539) | Sanofi | 2020-05-18 |
| Efficacy and Safety of Teicoplanin in CDAD (NCT04003818) | Sanofi | 2020-05-15 |
| Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia (NCT04349306) | Sanofi | 2020-05-14 |
| Hydroxychloroquine in Outpatient Adults With COVID-19 (NCT04333654) | Sanofi | 2020-04-12 |
| Sarilumab COVID-19 (NCT04327388) | Sanofi | 2020-03-28 |
| SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (NCT04154956) | Sanofi | 2020-02-06 |
| Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer (NCT04191382) | Sanofi | 2020-02-04 |